AI in Clinical Development: A CEO Conversation on Evidence, Accountability, and Patient Outcomes
Deepak explains where the evidence already supports AI, and where generative tools are moving into protocol writing and safety narratives on assumed reliability. He outlines how sponsors can align validation with FDA, EMA, and ICH expectations, what guardrails adaptive trials need when models keep learning, and why accountability stays with the sponsor even when the model comes from a vendor.